Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Orange Book Patents
Across 5 drugs with upcoming expirations
Activity
Last 14 days
Safety and Effects of Giving a New HIV Vaccine (GENEVAX-HIV) to HIV-Negative Volunteers
A Study of GENEVAX-HIV, a Possible Vaccine
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Regulatory
Protonix — PROTONIX
Application NDA020987
Protonix — PROTONIX IV
Application NDA020988
Protonix — PROTONIX
Application NDA020987
Protonix — PROTONIX
Application NDA022020
Protonix — PROTONIX IV
Application NDA020988
Protonix — PROTONIX
Application NDA022020
Protonix — PROTONIX
Application NDA020987
Effexor — EFFEXOR XR
Application NDA020699
Effexor — EFFEXOR XR
Application NDA020699
Effexor — EFFEXOR XR
Application NDA020699
Effexor — VENLAFAXINE BESYLATE
Application NDA215429 (NDA)
Protonix — PROTONIX IV
Application NDA020988
Protonix — PROTONIX
Application NDA022020
Protonix — PROTONIX
Application NDA020987
Effexor — EFFEXOR XR
Application NDA020699
Protonix — PROTONIX
Application NDA022020
Protonix — PROTONIX
Application NDA020987
Protonix — PROTONIX IV
Application NDA020988
Protonix — PROTONIX IV
Application NDA020988
Protonix — PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE
Application NDA217512 (NDA)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)